Moderna receives fda authorization for emergency use of its covid-19 vaccine for children 6 months of age and older

Mrna-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart mrna-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, with safety and tolerability profiles consistent with other age groups cambridge, ma / accesswire / june 17, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for its covid-19 vaccine (mrna-1273) in young children ages 6 months through 5 years of age at a dose level of 25 Μg. the company has also received emergency use authorization for a 50 Μg two-dose regimen of mrna-1273 for children ages 6 through 11 years old and a 100 Μg two-dose regimen for adolescents aged 12 through 17 years old.
MRNA Ratings Summary
MRNA Quant Ranking